Alpa Laboratories Limited

Alpa Laboratories Holds 38th AGM: Approves Director Re-appointments and ₹160 Crore Investment Limit

Alpa Laboratories held its 38th AGM on September 30, 2026. Key decisions included adopting FY26 financial statements, re-appointing directors Mr. Mahendra Singh Chawla and Mr. Paresh Chawla (MD), and appointing Mrs. Radhika Biyani as Independent Director. The company also approved an aggregate investment limit of ₹160 crores.

Alpa Laboratories Appoints Ms. Diksha Jaswani as Company Secretary Cum Compliance Officer

Alpa Laboratories Limited has appointed Ms. Diksha Jaswani as Company Secretary cum Compliance Officer (KMP). The appointment was approved by the Board on September 17, 2026. Ms. Jaswani is a qualified Company Secretary with extensive experience in regulatory processes.

Alpa Laboratories Ltd. Announces Book Closure for 38th AGM on Sep 23-30, 2026

Alpa Laboratories Limited announced book closure from September 23 to September 30, 2026, for its 38th Annual General Meeting. The AGM is scheduled for September 30, 2026.

Alpa Laboratories Appoints Radhika Biyani as Independent Director, Reconstitutes Committees

Alpa Laboratories appointed Mrs. Radhika Biyani as an Independent Director, effective September 5, 2026. The Board also reconstituted its Audit, Nomination and Remuneration, Stakeholders Relationship, and Risk Management Committees. The company has taken steps to improve director appointment processes.

Alpa Laboratories Clarifies Board Meeting Date to August 13, 2026

Alpa Laboratories Limited clarifies its Board Meeting date. The meeting is confirmed for August 13, 2026, at 3:00 PM at the registered office. A previous mention of August 14, 2026, was a typographical error.

Alpa Laboratories Explores Overseas Expansion in Nigeria

Alpa Laboratories is exploring the incorporation of an overseas company in Nigeria, named "Alpa Biopharm Limited," in partnership with Blueseal Pharmaceuticals Limited. The new entity will focus on pharmaceutical and healthcare businesses. This is an in-principle approval, with no investment made yet.

Alpa Laboratories Limited Clarifies Financial Results Submission on 23-Jul-2026

Alpa Laboratories Limited submitted revised financial results for the period ended March 31, 2026. The company confirmed the submission and dissemination of the information on July 23, 2026, via NEAPS. This filing relates to integrated financial results under Ind AS.

Alpa Laboratories Ltd: Independent Director Ms. Jyoti Jain Ceases Post-Tenure Completion

Ms. Jyoti Jain has ceased to be an Independent Director at Alpa Laboratories Limited. Her tenure concluded on July 21, 2026. The company has filed the necessary disclosures as per SEBI regulations.

Alpa Laboratories Approves Audited FY26 Financial Results, Appoints Internal and Cost Auditors

Alpa Laboratories Limited's Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company also appointed M/s S. S. Gandhi & Associates as Internal Auditor and M/s. Sudeep Saxena & Associates as Cost Auditor for FY 2026-27.

Alpa Laboratories Clarifies No Price-Sensitive Information Pending

Alpa Laboratories Limited has clarified to stock exchanges that there is no undisclosed price-sensitive information or upcoming event impacting its stock performance. The company confirmed full compliance with disclosure norms in response to an inquiry about recent price movements.

Alpa Laboratories: Srashti Chopra Resigns as Company Secretary, Effective March 25, 2026

Alpa Laboratories announced the resignation of Ms. Srashti Chopra as Company Secretary and Compliance Officer, effective March 25, 2026. The resignation, tendered on February 25, 2026, is due to personal reasons. Ms. Chopra will ensure a smooth transition during her notice period.

Alpa Labs Approves Q3 FY26 Unaudited Standalone & Consolidated Financial Results

Alpa Laboratories Limited's Board approved Q3 FY26 unaudited standalone and consolidated financial results. For the quarter ended December 31, 2025, standalone revenue from operations stood at ₹29.67 crore, and consolidated revenue from operations was ₹29.05 crore. Standalone and consolidated EPS for the quarter were ₹0.89 and ₹0.90, respectively.

Alpa Laboratories Declares Q3 FY26 Standalone & Consolidated Financial Results

Alpa Laboratories announced its Q3 FY26 results. For the quarter ended December 31, 2025, standalone profit after tax was ₹0.19 crore on revenue of ₹29.93 crore. Consolidated profit after tax was also ₹0.19 crore on revenue of ₹29.96 crore. For the nine months ended December 31, 2025, standalone profit after tax was ₹13.75 crore.

Alpa Laboratories Closes Trading Window from Jan 1, 2026, for Q3 FY26 Results

Alpa Laboratories Limited will close its trading window from January 1, 2026. The window will reopen 48 hours after the declaration of the unaudited financial results for the quarter ending December 31, 2025. This is in compliance with SEBI regulations.

Alpa Laboratories Approves Un-Audited Standalone & Consolidated Financial Results for Quarter Ended 30 Sep 2025

Alpa Labs board approves unaudited standalone and consolidated results for quarter ended 30 Sep 2025 in board meeting held on 14 Nov 2025.

Alpa Laboratories Submits Voting Results and Scrutinizer's Report for AGM

Alpa Laboratories announces book closure for AGM